Metformin

Biguanides and lactic acidosis in diabetics.
[589254] Br Med J 2(6100): 1436 (1977)

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.
[14638559] Arch Intern Med 163(21): 2594-602 (2003)

Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.
[11863476] Arch Intern Med 162(4): 434-7 (2002)

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
[15189360] J Intern Med 256(1): 1-14 (2004)

Metformin and lactic acidosis: cause or coincidence? A review of case reports.
[14746555] J Intern Med 255(2): 179-87 (2004)

Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment.
[18490795] Neth J Med 66(5): 185-90 (2008)

Metformin: evidence-based versus rational pharmacotherapy.
[12365465] Neth J Med 60(6): 228-30 (2002)

Treating prediabetes with metformin: systematic review and meta-analysis.
[19366942] Can Fam Physician 55(4): 363-9 (2009)

Metformin as treatment for overweight and obese adults: a systematic review.
[16189063] Ann Fam Med 3(5): 457-61 (2005)

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
[18200815] Vasc Health Risk Manag 3(6): 967-73 (2007)

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
[17969380] Vasc Health Risk Manag 3(4): 503-10 (2007)

ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes.
[19391221] Ann Intern Med 150(8): JC4-8 (2009)

Combination of insulin and metformin in the treatment of type 2 diabetes.
[12453950] Diabetes Care 25(12): 2133-40 (2002)

First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization.
[10333901] Diabetes Care 22(1): 38-44 (1999)

Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
[10333900] Diabetes Care 22(1): 33-7 (1999)

Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management.
[17296508] Diabetes Metab 32(6): 555-6 (2006)

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications.
[15671920] Diabetes Metab 30(6): 509-16 (2004)

The potential of metformin for diabetes prevention.
[14502107] Diabetes Metab 29(4 Pt 2): 6S104-11 (2003)

Metformin inhibition of glycation processes.
[14502106] Diabetes Metab 29(4 Pt 2): 6S95-103 (2003)

Mitochondrial metabolism and type-2 diabetes: a specific target of metformin.
[14502105] Diabetes Metab 29(4 Pt 2): 6S88-94 (2003)

Antiatherogenic properties of metformin: the experimental evidence.
[14502103] Diabetes Metab 29(4 Pt 2): 6S71-6 (2003)

Do effects on blood pressure contribute to improved clinical outcomes with metformin?
[14502102] Diabetes Metab 29(4 Pt 2): 6S62-70 (2003)

Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
[14502101] Diabetes Metab 29(4 Pt 2): 6S53-61 (2003)

Beneficial effects of metformin on haemostasis and vascular function in man.
[14502100] Diabetes Metab 29(4 Pt 2): 6S44-52 (2003)

Improving survival with metformin: the evidence base today.
[14502099] Diabetes Metab 29(4 Pt 2): 6S36-43 (2003)

Reducing insulin resistance with metformin: the evidence today.
[14502098] Diabetes Metab 29(4 Pt 2): 6S28-35 (2003)

Pharmacogenetics of metformin response: a step in the path toward personalized medicine.
[17476355] J Clin Invest 117(5): 1226-9 (2007)

Frequency of inappropriate metformin prescriptions.
[12020329] JAMA 287(19): 2504-5 (2002)

Metformin's contraindications: needed for now.
[16129872] CMAJ 173(5): 505-7 (2005)

Metformin's contraindications should be contraindicated.
[16129871] CMAJ 173(5): 502-4 (2005)

Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.
[20032157] Radiology 254(1): 261-9 (2010)

Contraindications to the use of metformin.
[12511434] BMJ 326(7379): 4-5 (2003)

Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
[17823192] BMJ 335(7618): 508-12 (2007)

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
[20305377] Cell Cycle 9(6): 1057-64 (2010)

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.
[19841045] Eur J Endocrinol 162(2): 193-212 (2010)

Insulin-lowering agents in the management of polycystic ovary syndrome.
[14570747] Endocr Rev 24(5): 633-67 (2003)

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
[19056992] Endocr Rev 30(1): 1-50 (2009)

An energetic tale of AMPK-independent effects of metformin.
[20577046] J Clin Invest 120(7): 2267-70 (2010)

Metformin: a therapeutic opportunity in breast cancer.
[20215559] Clin Cancer Res 16(6): 1695-700 (2010)

Metformin and serious adverse effects.
[14723582] Med J Aust 180(2): 53-4 (2004)

Metformin and serious adverse effects.
[15233618] Med J Aust 181(1): 56 (2004)

Metformin for obesity in children and adolescents: a systematic review.
[19502540] Diabetes Care 32(9): 1743-5 (2009)

Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo.
[20299472] Diabetes 59(6): 1386-96 (2010)

Understanding the benefit of metformin use in cancer treatment.
[21470407] BMC Med 9(-): 33 (2011)

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
[21765869] Therap Adv Gastroenterol 4(4): 249-63 (2011)

Metformin: the safest hypoglycaemic agent in chronic kidney disease?
[21325870] Nephron Clin Pract 118(4): c380-3 (2011)

Metformin and other biguanides in oncology: advancing the research agenda.
[20810670] Cancer Prev Res (Phila) 3(9): 1060-5 (2010)

AMPK as a mediator of hormonal signalling.
[19625456] J Mol Endocrinol 44(2): 87-97 (2010)

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
[20442309] Mol Cancer Ther 9(5): 1092-9 (2010)

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
[23055147] Hepatology 57(2):648-55 (2013)

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
[24648894] Biomed Rep 1(1):57-64 (2013)

Metformin-associated lactic acidosis (MALA): case files of the Einstein Medical Center medical toxicology fellowship.
[23233435] J Med Toxicol 9(1):61-6 (2013)

Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation.
[23449430] J Am Coll Cardiol 61(9):971-80 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Metformin.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Metformin.php on line 92